Press Releases

2021

Lilly’s SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

June 28, 2021

Lilly launches “The Leonard Award” as part of a global initiative commemorating the discovery of insulin 100 years ago

June 24, 2021

Notice of Compliance with Conditions granted for Retevmo™ (selpercatinib), the first therapy in Canada specifically for patients with advanced RET-driven lung and thyroid cancers

June 21, 2021

Lilly announces new clinical data from Verzenio and oral SERD programs at the American Society of Clinical Oncology annual meeting

June 14, 2021

Taltz® delivers more cumulative days with completely clear skin for adults with psoriasis compared to seven other biologics in novel network meta-analysis

April 30, 2021

Olumiant® showed significant improvements in the severity and extent of atopic dermatitis and other patient-reported outcomes in Phase 3 study analyses

April 30, 2021

Lilly presents new data on selpercatinib in advanced RET fusion-positive gastrointestinal and other cancers at 2021 American Association for Cancer Research (AACR) annual meeting

April 20, 2021

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

April 16, 2021

Taltz® (ixekizumab) approved by Health Canada for the treatment of pediatric patients (six to less than 18 years of age) with moderate- to severe plaque psoriasis

April 2, 2021

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

March 15, 2021

Emgality® (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

February 25, 2021

New data show treatment with Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 per cent

January 26, 2021

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 per cent for residents

January 21, 2021


2020

Data from ACTT-2 trial of baricitinib in hospitalized COVID-19 patients supportive of the U. S. FDA EUA published in New England Journal of Medicine

December 19, 2020

Lilly’s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes

December 14, 2020

Lilly and the Government of Canada sign an agreement for the supply of bamlanivimab to treat COVID-19 in Canada

November 24, 2020

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19

November 20, 2020

Ontario Brain Institute and Eli Lilly Canada collaborate to train future Canadian neuroscience leaders

November 12, 2020

Health Canada has approved Taltz® (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA)

October 19, 2020

Baricitinib has significant effect on recovery time, most impactful in patients with COVID-19 requiring oxygen

October 16, 2020

Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs

October 8, 2020

Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

September 24, 2020

Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease

September 22, 2020

Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-2 trial

September 17, 2020

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

September 16, 2020

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

September 8, 2020

Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections

June 19, 2020

Lilly begins a Phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients

June 18, 2020

EULAR 2020: Lilly shares new data for Olumiant® in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)

June 10, 2020

EULAR 2020: Lilly’s Taltz® (ixekizumab) continues to show robust and consistent efficacy in psoriatic arthritis

June 5, 2020

Health Canada has approved Taltz® (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis)

February 11, 2020

Lilly and Incyte announce positive top-line results from the North American Phase 3 study (BREEZE-AD5) of oral selective JAK inhibitor baricitinib in patients with moderate- to severe atopic dermatitis

February 11, 2020

Ready for Rescue – New nasally administered glucagon for severe hypoglycemia available in Canada

January 23, 2020


2019

ACR 2019: Lilly presents 52-week head-to-head (SPIRIT-H2H) data from TALTZ® (ixekizumab) versus Humira® (adalimumab) trial in psoriatic arthritis

November 26, 2019

ACR 2019: Lilly presents positive new data from COAST-X, a Phase 3 study of TALTZ® (ixekizumab) in patients with non-radiographic axial spondyloarthritis

November 26, 2019

New head-to-head data show TALTZ® (ixekizumab) superiority versus TREMFYA® (guselkumab) in people with moderate to severe plaque psoriasis

October 10, 2019

Verzenio™ (abemaciclib) significantly extends life by a median of 9.4 months for women with HR+, HER2- advanced breast cancer in MONARCH 2 study

October 4, 2019

EMGALITY™ (galcanezumab) now available in Canada for preventive treatment of migraine

October 2, 2019

Lilly announces superiority of TALTZ® (ixekizumab) versus TREMFYA® (guselkumab) in delivering total skin clearance at week 12 in topline results from head-to-head (IXORA-R) trial in people living with moderate to severe plaque psoriasis

August 14, 2019

VERZENIO™ (abemaciclib) available in Canada for metastatic breast cancer

August 8, 2019

Lilly announces positive results for Emgality™ (galcanezumab) from the CONQUER study in patients who failed previous migraine preventive treatments

August 8, 2019

Lilly presents positive results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head (SPIRIT-H2H) superiority study in patients with active psoriatic arthritis at the European Congress of Rheumatology

June 14, 2019

Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes

June 10, 2019

Lilly’s mirikizumab met primary endpoint and key secondary endpoints in Phase 2 study, including reductions of gastrointestinal lesions

May 22, 2019

Lilly announces top-line Phase 3 results for baricitinib in patients with moderate to severe atopic dermatitis

February 4, 2019


2018

Lilly announces positive top-line results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head superiority study (SPIRIT-H2H) in patients with active psoriatic arthritis

December 17, 2018

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease

November 6, 2018

Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes

November 5, 2018

With availability of Olumiant™ (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

November 1, 2018

Eli Lilly Canada and Women in Biz Network partner to shift perceptions of rheumatoid arthritis in the workplace

October 12, 2018

Lilly’s investigational dual GIP and GLP-1 receptor agonist shows significant reduction in HbA1c and body weight in people with type 2 diabetes

October 9, 2018

Health Canada approves Taltz® (ixekizumab) for treatment of active psoriatic arthritis

June 20, 2018

Convenient prefilled insulin pen with flexible half-unit dosing approved and available in Canada

May 3, 2018

LARTRUVO™ (olaratumab) approved in Canada for the treatment of advanced soft tissue sarcoma in adults

January 24, 2018


2017

New concentrated insulin approved and available for Canadian patients

December 12, 2017

What matters most to Canadians living with rheumatoid arthritis?

October 26, 2017

Deeper than just skin, World Psoriasis Day spotlights the disease’s human impact

October 25, 2017

Acclaimed musician and former American Idol in Toronto for a special performance for children with type 1 diabetes

August 31, 2017

New report reveals little progress on 2014 WHO psoriasis recommendations

April 18, 2017


2016

Health Canada approves new indication for JARDIANCE™ (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease

August 11, 2016

Health Canada’s approval of Taltz™ (ixekizumab) brings targeted therapy to Canadians living with moderate-to-severe plaque psoriasis

June 21, 2016

JARDIANCE® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease

June 14, 2016

Trulicity™, a once-weekly GLP-1 injectable medication, now available to help Canadians with type 2 diabetes manage their blood sugar

February 16, 2016